Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance models
J Clin Invest. 2024 Feb 29:e161941. doi: 10.1172/JCI161941. Online ahead of print.ABSTRACTRAD54 and BLM helicase play pivotal roles during homologous recombination repair (HRR) ensuring genome maintenance. BLM amino acids (181-212) interacts with RAD54 and enhances its chromatin remodelling activity. Functionally, this interaction heightens HRR, leading to a decrease in residual DNA damage in colon cancer cells. This contributes to chemoresistance in colon cancer cells against cisplatin, camptothecin and oxaliplatin, eventually promoting tumorigenesis in preclinical colon cancer mouse models. ChIP-seq analysis and validati...
Source: Clinical Colorectal Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Ekjot Kaur Ritu Agrawal Rimpy Arun Vinoth Madhavan Vivek Srivastava Dilip Kumar Pragyan Parimita Rath Nitin Kumar Sreekanth Vedagopuram Nishant Pandey Swati Priya Patrick Legembre Samudrala Gourinath Avinash Bajaj Sagar Sengupta Source Type: research
Low molecular weight fucoidan LF2 improves the immunosuppressive tumor microenvironment and enhances the anti-pancreatic cancer activity of oxaliplatin
In this study, we found that low molecular weight of fucoidan (LF2) directly regulated the differentiation of mononuclear macrophages into the CD86+ M1 phenotype. LF2 significantly upregulated the expressions of M1 macrophage-specific cytokines, including iNOS, IL-6, TNFα and IL-12. LF2 modulated macrophage phenotypic transformation through activation of TLR4-NFκB pathway. Furthermore, we observed that LF2 enhanced the pro-apoptotic activity of oxaliplatin (OXA) in vitro by converting macrophages to a tumoricidal M1 phenotype. Meanwhile, LF2 increased intratumoral M1 macrophage infiltration and ameliorated the immunosupp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 29, 2024 Category: Drugs & Pharmacology Authors: Zhenzhen Deng Suo Qishan Quanbin Zhang Jing Wang Yang Yue Lihua Geng Ning Wu Source Type: research
Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.PMID:38419314 | DOI:10.18926/AMO/66670 (Source: Acta Med Okayama)
Source: Acta Med Okayama - February 29, 2024 Category: Universities & Medical Training Authors: Manabu Shimomura Katsunori Shinozaki Takuya Yano Shintaro Akabane Hideki Ohdan Hiroshima Surgical study group of Clinical Oncology (HiSCO) Source Type: research
Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.PMID:38419314 | DOI:10.18926/AMO/66670 (Source: Acta Medica Okayama)
Source: Acta Medica Okayama - February 29, 2024 Category: General Medicine Authors: Manabu Shimomura Katsunori Shinozaki Takuya Yano Shintaro Akabane Hideki Ohdan Hiroshima Surgical study group of Clinical Oncology (HiSCO) Source Type: research
Low molecular weight fucoidan LF2 improves the immunosuppressive tumor microenvironment and enhances the anti-pancreatic cancer activity of oxaliplatin
In this study, we found that low molecular weight of fucoidan (LF2) directly regulated the differentiation of mononuclear macrophages into the CD86+ M1 phenotype. LF2 significantly upregulated the expressions of M1 macrophage-specific cytokines, including iNOS, IL-6, TNFα and IL-12. LF2 modulated macrophage phenotypic transformation through activation of TLR4-NFκB pathway. Furthermore, we observed that LF2 enhanced the pro-apoptotic activity of oxaliplatin (OXA) in vitro by converting macrophages to a tumoricidal M1 phenotype. Meanwhile, LF2 increased intratumoral M1 macrophage infiltration and ameliorated the immunosupp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 29, 2024 Category: Drugs & Pharmacology Authors: Zhenzhen Deng Suo Qishan Quanbin Zhang Jing Wang Yang Yue Lihua Geng Ning Wu Source Type: research
Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.PMID:38419314 | DOI:10.18926/AMO/66670 (Source: Acta Med Okayama)
Source: Acta Med Okayama - February 29, 2024 Category: Universities & Medical Training Authors: Manabu Shimomura Katsunori Shinozaki Takuya Yano Shintaro Akabane Hideki Ohdan Hiroshima Surgical study group of Clinical Oncology (HiSCO) Source Type: research
Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.PMID:38419314 | DOI:10.18926/AMO/66670 (Source: Acta Medica Okayama)
Source: Acta Medica Okayama - February 29, 2024 Category: General Medicine Authors: Manabu Shimomura Katsunori Shinozaki Takuya Yano Shintaro Akabane Hideki Ohdan Hiroshima Surgical study group of Clinical Oncology (HiSCO) Source Type: research
Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.PMID:38419314 | DOI:10.18926/AMO/66670 (Source: Acta Med Okayama)
Source: Acta Med Okayama - February 29, 2024 Category: Universities & Medical Training Authors: Manabu Shimomura Katsunori Shinozaki Takuya Yano Shintaro Akabane Hideki Ohdan Hiroshima Surgical study group of Clinical Oncology (HiSCO) Source Type: research
Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.PMID:38419314 | DOI:10.18926/AMO/66670 (Source: Acta Medica Okayama)
Source: Acta Medica Okayama - February 29, 2024 Category: General Medicine Authors: Manabu Shimomura Katsunori Shinozaki Takuya Yano Shintaro Akabane Hideki Ohdan Hiroshima Surgical study group of Clinical Oncology (HiSCO) Source Type: research
Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.PMID:38419314 | DOI:10.18926/AMO/66670 (Source: Acta Med Okayama)
Source: Acta Med Okayama - February 29, 2024 Category: Universities & Medical Training Authors: Manabu Shimomura Katsunori Shinozaki Takuya Yano Shintaro Akabane Hideki Ohdan Hiroshima Surgical study group of Clinical Oncology (HiSCO) Source Type: research
Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.PMID:38419314 | DOI:10.18926/AMO/66670 (Source: Acta Medica Okayama)
Source: Acta Medica Okayama - February 29, 2024 Category: General Medicine Authors: Manabu Shimomura Katsunori Shinozaki Takuya Yano Shintaro Akabane Hideki Ohdan Hiroshima Surgical study group of Clinical Oncology (HiSCO) Source Type: research
Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.PMID:38419314 | DOI:10.18926/AMO/66670 (Source: Acta Med Okayama)
Source: Acta Med Okayama - February 29, 2024 Category: Universities & Medical Training Authors: Manabu Shimomura Katsunori Shinozaki Takuya Yano Shintaro Akabane Hideki Ohdan Hiroshima Surgical study group of Clinical Oncology (HiSCO) Source Type: research
Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.PMID:38419314 | DOI:10.18926/AMO/66670 (Source: Acta Medica Okayama)
Source: Acta Medica Okayama - February 29, 2024 Category: General Medicine Authors: Manabu Shimomura Katsunori Shinozaki Takuya Yano Shintaro Akabane Hideki Ohdan Hiroshima Surgical study group of Clinical Oncology (HiSCO) Source Type: research
Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.PMID:38419314 | DOI:10.18926/AMO/66670 (Source: Acta Med Okayama)
Source: Acta Med Okayama - February 29, 2024 Category: Universities & Medical Training Authors: Manabu Shimomura Katsunori Shinozaki Takuya Yano Shintaro Akabane Hideki Ohdan Hiroshima Surgical study group of Clinical Oncology (HiSCO) Source Type: research
Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.PMID:38419314 | DOI:10.18926/AMO/66670 (Source: Acta Medica Okayama)
Source: Acta Medica Okayama - February 29, 2024 Category: General Medicine Authors: Manabu Shimomura Katsunori Shinozaki Takuya Yano Shintaro Akabane Hideki Ohdan Hiroshima Surgical study group of Clinical Oncology (HiSCO) Source Type: research
